SCHEMBL6174044

SCHEMBL6174044

O=C(O)CNc1ccccc1C(=O)c1ccc(F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 3/20 0.59
KDM4E B2RXH2 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
BDKRB1 P46663 1/20 0.46
HPGD P15428 4/20 0.44
NPC1 O15118 2/20 0.44
MAPT P10636 2/20 0.44
ALOX12 P18054 2/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698881 0.89 AGTR1 (0.60) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL9716675 0.86 LIG1 (0.53) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL9716698 0.85 AGTR1 (0.49) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL10660692 0.85 AGTR1 (0.59) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL8923851 0.85 AKR1C3 (0.57) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL10659074 0.81 KMT2A (0.48) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL6570855 0.81 KMT2A (0.64) KDM4EALDH1A1KMT2AMEN1HPGD
Benzene SCHEMBL28318261 0.78 AKR1C3 (0.61) ALDH1A1KMT2AMEN1HPGDNPC1
SCHEMBL341645 0.77 KDM4E (0.71) AGTR1KDM4ERAB9AALDH1A1KMT2A
SCHEMBL29620333 0.77 KDM4E (0.71) AGTR1KDM4ERAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949543-B2 Amide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 US disclosed
EP-1340750-B1 AMIDE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 EP disclosed
US-20040034232-A1 Amide derivative ASTELLAS PHARMA INC. (JP) 2004-02-19 US disclosed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 EP disclosed
US-6008235-A Pyridyl substituted imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1999-12-28 US disclosed
EP-0624159-B1 PYRIDYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORP (US) 1998-11-25 EP disclosed
US-5716972-A Pyridyl substituted imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1998-02-10 US disclosed
EP-0624159-A4 PYRIDYL SUBSTITUTED IMIDAZOLES. SMITHKLINE BEECHAM CORP (US) 1995-04-12 EP disclosed
EP-0624159-A1 PYRIDYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1994-11-17 EP disclosed
WO-1993014082-A1 PYRIDYL SUBSTITUTED IMIDAZOLES SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034232-A1 Amide derivative HDAC2, ZC3HAV1, HDAC4 AGTR1 4243/4885KDM4E 17/4885RAB9A 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.